SOUTH SAN FRANCISCO, Calif.,
Oct. 10, 2017 /PRNewswire/ -- Rigel
Pharmaceuticals, Inc. (NasdaqGS: RIGL) today announced the closing
of its previously announced underwritten public offering of
20,815,000 shares of its common stock at a price to the public of
$3.35 per share, which includes
2,715,000 additional shares of common stock issued upon the
exercise in full of the underwriters' option to purchase additional
shares. The gross proceeds to Rigel from this offering are
$69,730,250, before deducting
underwriting discounts and commissions and other estimated offering
expenses payable by Rigel. All of the shares in the offering
were sold by Rigel.
Jefferies LLC and BMO Capital Markets Corp. acted as joint
book-running managers for the offering. H.C. Wainwright &
Co., LLC acted as lead manager for the offering.
A shelf registration statement on Form S-3 relating to the
public offering of the shares of common stock described above was
filed with the Securities and Exchange Commission (the "SEC") and
is effective. A final prospectus supplement and accompanying
prospectus relating to the offering have been filed with the SEC
and are available on the SEC's web site at www.sec.gov.
Copies of the final prospectus supplement may also be
obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877)
547-6340, or by e-mail at Prospectus_Department@Jefferies.com, or
from BMO Capital Markets Corp., Attention: Equity Syndicate
Department, 3 Times Square, 25th Floor, New York, NY 10036, or by telephone at (800)
414-3627 or by email at bmoprospectus@bmo.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Rigel Pharmaceuticals, Inc.
Rigel
Pharmaceuticals, Inc. is a biotechnology company dedicated to
discovering, developing and providing novel small molecule drugs
that significantly improve the lives of patients with immune and
hematological disorders, cancer and rare diseases. Rigel's
pioneering research focuses on signaling pathways that are critical
to disease mechanisms. The company's current clinical programs
include clinical trials of fostamatinib, an oral spleen tyrosine
kinase (SYK) inhibitor, in a number of indications. Rigel has
submitted an NDA to the FDA for fostamatinib in patients with
chronic or persistent immune thrombocytopenia (ITP). In addition,
Rigel has product candidates in development with partners BerGenBio
AS, Daiichi Sankyo and Aclaris Therapeutics.
Contact: Raul Rodriguez
Phone: 650.624.1302
Email: invrel@rigel.com
Media Contact: Jessica Daitch
Phone: 917.816.6712
Email: jessica.daitich@inventivhealth.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/rigel-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-option-to-purchase-additional-shares-300534200.html
SOURCE Rigel Pharmaceuticals, Inc.